Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Shashi Gujar; Jonathan G. Pol; Youra Kim; Patrick W. Lee; Guido Kroemer

doi:10.1016/j.it.2017.11.006

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Shashi Gujar, Jonathan G. Pol, Youra Kim, Patrick W. Lee, Guido Kroemer

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

168 Citas (Scopus)

Resumen

Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor. While antitumor immunity is beneficial, antiviral immune responses are often considered detrimental for the efficacy of OV-based therapy. The existing dogma postulates that anti-OV immune responses restrict viral replication and spread, and thus reduce direct OV-mediated killing of cancer cells. Accordingly, a myriad of therapeutic strategies aimed at mitigating anti-OV immune responses is presently being tested. Here, we advocate that OV-induced antiviral immune responses hold intrinsic anticancer benefits and are essential for establishing clinically desired antitumor immunity. Thus, to achieve the optimal efficacy of OV-based cancer immunotherapies, strategic management of anti-OV immune responses is of critical importance.

Idioma original	English
Páginas (desde-hasta)	209-221
Número de páginas	13
Publicación	Trends in Immunology
Volumen	39
N.º	3
DOI	https://doi.org/10.1016/j.it.2017.11.006
Estado	Published - mar. 2018

Nota bibliográfica

Funding Information:
S.G. and P.W.L. are supported by grants from the Canadian Institutes of Health Research (CIHR) , Terry Fox Research Institute (TFRI) , and Canadian Cancer Research Institute (CCSRI) . Y.K. is currently supported by the CIHR Doctoral Award. G.K.’s team is supported by the French Ligue Contre le Cancer (equipe labellisée); Agence Nationale de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Île-de-France; Institut National du Cancer (INCa); L’Institut Universitaire de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the Leducq Foundation; the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Publisher Copyright:
© 2017 Elsevier Ltd

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.it.2017.11.006

Otros archivos y enlaces

Citar esto

@article{335b873e5eab4e64a404659f94b4cc93,

title = "Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies",

abstract = "Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor. While antitumor immunity is beneficial, antiviral immune responses are often considered detrimental for the efficacy of OV-based therapy. The existing dogma postulates that anti-OV immune responses restrict viral replication and spread, and thus reduce direct OV-mediated killing of cancer cells. Accordingly, a myriad of therapeutic strategies aimed at mitigating anti-OV immune responses is presently being tested. Here, we advocate that OV-induced antiviral immune responses hold intrinsic anticancer benefits and are essential for establishing clinically desired antitumor immunity. Thus, to achieve the optimal efficacy of OV-based cancer immunotherapies, strategic management of anti-OV immune responses is of critical importance.",

author = "Shashi Gujar and Pol, {Jonathan G.} and Youra Kim and Lee, {Patrick W.} and Guido Kroemer",

note = "Funding Information: S.G. and P.W.L. are supported by grants from the Canadian Institutes of Health Research (CIHR) , Terry Fox Research Institute (TFRI) , and Canadian Cancer Research Institute (CCSRI) . Y.K. is currently supported by the CIHR Doctoral Award. G.K.{\textquoteright}s team is supported by the French Ligue Contre le Cancer (equipe labellis{\'e}e); Agence Nationale de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le {\^I}le-de-France; Institut National du Cancer (INCa); L{\textquoteright}Institut Universitaire de France; Fondation pour la Recherche M{\'e}dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the Leducq Foundation; the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2018",

month = mar,

doi = "10.1016/j.it.2017.11.006",

language = "English",

volume = "39",

pages = "209--221",

journal = "Trends in Immunology",

issn = "1471-4906",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Antitumor Benefits of Antiviral Immunity

T2 - An Underappreciated Aspect of Oncolytic Virotherapies

AU - Gujar, Shashi

AU - Pol, Jonathan G.

AU - Kim, Youra

AU - Lee, Patrick W.

AU - Kroemer, Guido

N1 - Funding Information: S.G. and P.W.L. are supported by grants from the Canadian Institutes of Health Research (CIHR) , Terry Fox Research Institute (TFRI) , and Canadian Cancer Research Institute (CCSRI) . Y.K. is currently supported by the CIHR Doctoral Award. G.K.’s team is supported by the French Ligue Contre le Cancer (equipe labellisée); Agence Nationale de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Île-de-France; Institut National du Cancer (INCa); L’Institut Universitaire de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the Leducq Foundation; the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Publisher Copyright: © 2017 Elsevier Ltd

PY - 2018/3

Y1 - 2018/3

N2 - Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor. While antitumor immunity is beneficial, antiviral immune responses are often considered detrimental for the efficacy of OV-based therapy. The existing dogma postulates that anti-OV immune responses restrict viral replication and spread, and thus reduce direct OV-mediated killing of cancer cells. Accordingly, a myriad of therapeutic strategies aimed at mitigating anti-OV immune responses is presently being tested. Here, we advocate that OV-induced antiviral immune responses hold intrinsic anticancer benefits and are essential for establishing clinically desired antitumor immunity. Thus, to achieve the optimal efficacy of OV-based cancer immunotherapies, strategic management of anti-OV immune responses is of critical importance.

AB - Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor. While antitumor immunity is beneficial, antiviral immune responses are often considered detrimental for the efficacy of OV-based therapy. The existing dogma postulates that anti-OV immune responses restrict viral replication and spread, and thus reduce direct OV-mediated killing of cancer cells. Accordingly, a myriad of therapeutic strategies aimed at mitigating anti-OV immune responses is presently being tested. Here, we advocate that OV-induced antiviral immune responses hold intrinsic anticancer benefits and are essential for establishing clinically desired antitumor immunity. Thus, to achieve the optimal efficacy of OV-based cancer immunotherapies, strategic management of anti-OV immune responses is of critical importance.

UR - http://www.scopus.com/inward/record.url?scp=85038923491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038923491&partnerID=8YFLogxK

U2 - 10.1016/j.it.2017.11.006

DO - 10.1016/j.it.2017.11.006

M3 - Review article

C2 - 29275092

AN - SCOPUS:85038923491

SN - 1471-4906

VL - 39

SP - 209

EP - 221

JO - Trends in Immunology

JF - Trends in Immunology

IS - 3

ER -

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto